139 related articles for article (PubMed ID: 11418362)
1. Occurrence of HIV-1 reverse transcriptase gene mutation at codon 215 in HIV-infected infants.
Kamkamidze G; Sullivan T; Charbonneau T
J Clin Virol; 2001 Aug; 22(1):143-8. PubMed ID: 11418362
[TBL] [Abstract][Full Text] [Related]
2. Selective vertical transmission of HIV-1 antiretroviral resistance mutations.
Colgrove RC; Pitt J; Chung PH; Welles SL; Japour AJ
AIDS; 1998 Dec; 12(17):2281-8. PubMed ID: 9863870
[TBL] [Abstract][Full Text] [Related]
3. HIV-1 genotypic zidovudine drug resistance and the risk of maternal--infant transmission in the women and infants transmission study. The Women and Infants Transmission Study Group.
Welles SL; Pitt J; Colgrove R; McIntosh K; Chung PH; Colson A; Lockman S; Fowler MG; Hanson C; Landesman S; Moye J; Rich KC; Zorrilla C; Japour AJ
AIDS; 2000 Feb; 14(3):263-71. PubMed ID: 10716502
[TBL] [Abstract][Full Text] [Related]
4. HIV-1 reverse transcriptase codon 215 mutation in plasma RNA: immunologic and virologic responses to zidovudine. The AIDS Clinical Trials Group Study 175 Virology Team.
Rey D; Hughes M; Pi JT; Winters M; Merigan TC; Katzenstein DA
J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Mar; 17(3):203-8. PubMed ID: 9495218
[TBL] [Abstract][Full Text] [Related]
5. Effect of perinatal short-course zidovudine on the clinical and virological manifestations of HIV-1 subtype E infection in infants.
Sutthent R; Chokephaibulkit K; Piyasujabul D; Vanprapa N; Roogpisuthipong A; Chaisilwatana P
J Clin Virol; 2002 Jul; 25(1):47-56. PubMed ID: 12126721
[TBL] [Abstract][Full Text] [Related]
6. Carrier rate of zidovudine-resistant HIV-1: the impact of failing therapy on transmission of resistant strains.
Goudsmit J; Weverling GJ; van der Hoek L; de Ronde A; Miedema F; Coutinho RA; Lange JM; Boerlijst MC
AIDS; 2001 Nov; 15(17):2293-301. PubMed ID: 11698703
[TBL] [Abstract][Full Text] [Related]
7. Zidovudine genotypic resistance in HIV-1-infected newborns in the French perinatal cohort.
Masquelier B; Chaix ML; Burgard M; Lechenadec J; Doussin A; Simon F; Cottalorda J; Izopet J; Tamalet C; Douard D; Fleury H; Mayaux MJ; Blanche S; Rouzioux C;
J Acquir Immune Defic Syndr; 2001 Jun; 27(2):99-104. PubMed ID: 11404530
[TBL] [Abstract][Full Text] [Related]
8. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.
Siegfried N; van der Merwe L; Brocklehurst P; Sint TT
Cochrane Database Syst Rev; 2011 Jul; (7):CD003510. PubMed ID: 21735394
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain.
Gómez-Cano M; Rubio A; Puig T; Pérez-Olmeda M; Ruiz L; Soriano V; Pineda JA; Zamora L; Xaus N; Clotet B; Leal M
AIDS; 1998 Jun; 12(9):1015-20. PubMed ID: 9662197
[TBL] [Abstract][Full Text] [Related]
10. Genotypic resistance to zidovudine as a predictor of failure of subsequent therapy with human immunodeficiency virus type-1 nucleoside reverse-transcriptase inhibitors.
Venturi G; Romano L; Catucci M; Riccio ML; De Milito A; Gonnelli A; Rubino M; Valensin PE; Zazzi M
Eur J Clin Microbiol Infect Dis; 1999 Apr; 18(4):274-82. PubMed ID: 10385016
[TBL] [Abstract][Full Text] [Related]
11. The reverse transcriptase codon 69 insertion is observed in nucleoside reverse transcriptase inhibitor-experienced HIV-1-infected individuals, including those without prior or concurrent zidovudine therapy.
Ross L; Johnson M; Graham N; Shaefer M; St Clair M
J Hum Virol; 1999; 2(5):290-5. PubMed ID: 10551735
[TBL] [Abstract][Full Text] [Related]
12. Development and significance of the HIV-1 reverse transcriptase M184V mutation during combination therapy with lamivudine, zidovudine, and protease inhibitors.
Catucci M; Venturi G; Romano L; Riccio ML; De Milito A; Valensin PE; Zazzi M
J Acquir Immune Defic Syndr; 1999 Jul; 21(3):203-8. PubMed ID: 10421243
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of didanosine and drug resistance mutations in infants exposed to zidovudine during gestation or postnatally and treated with didanosine or zidovudine in the first three months of life.
Kovacs A; Cowles MK; Britto P; Capparelli E; Fowler MG; Moye J; McIntosh K; Rathore MH; Pitt J; Husson RN
Pediatr Infect Dis J; 2005 Jun; 24(6):503-9. PubMed ID: 15933559
[TBL] [Abstract][Full Text] [Related]
14. Zidovudine therapy and HIV type 1 mutations in children with symptomatic HIV type 1 infection: effect of switching to didanosine or zidovudine plus didanosine therapy. Italian Multicenter Study Group on HIV Mutations in Children.
Principi N; Marchisio P; Esposito S; Rossi P; Gattinara GC; Galli L; Gabiano C; Zuccotti GV; Orlandi P
AIDS Res Hum Retroviruses; 1998 Dec; 14(18):1653-9. PubMed ID: 9870319
[TBL] [Abstract][Full Text] [Related]
15. Nucleoside analogue mutations and Q151M in HIV-1 subtype A/E infection treated with nucleoside reverse transcriptase inhibitors.
Sirivichayakul S; Ruxrungtham K; Ungsedhapand C; Techasathit W; Ubolyam S; Chuenyam T; Emery S; Cooper D; Lange J; Phanuphak P
AIDS; 2003 Sep; 17(13):1889-96. PubMed ID: 12960821
[TBL] [Abstract][Full Text] [Related]
16. Analysis of HIV-1 reverse transcriptase gene mutations in infected children treated with zidovudine.
Orlandi P; Cancrini C; Scaccia S; Romiti ML; Livadiotti S; Gattinara GC; Angelini F; Cox S; Rossi P
J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Nov; 19(3):230-7. PubMed ID: 9803964
[TBL] [Abstract][Full Text] [Related]
17. Effect of pregnancy and zidovudine therapy on viral load in HIV-1-infected women.
Melvin AJ; Burchett SK; Watts DH; Hitti J; Hughes JP; McLellan CL; King PD; Johnson EJ; Williams BL; Frenkel LM; Coombs RW
J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Mar; 14(3):232-6. PubMed ID: 9117455
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of primary resistance to zidovudine and lamivudine in drug-naive human immunodeficiency virus type-1 infected patients: high proportion of reverse transcriptase codon 215 mutant in circulating lymphocytes and free virus.
Trabaud MA; Leriche-Guerin K; Regis C; Bordes I; Cotte L; Detmer J; Kolberg J; Ritter J; Trépo C
J Med Virol; 2000 Jul; 61(3):352-9. PubMed ID: 10861645
[TBL] [Abstract][Full Text] [Related]
19. A genotypic analysis of patients receiving Zidovudine with either Lamivudine, Didanosine or Zalcitabine dual therapy using the LiPA point mutation assay to detect genotypic variation at codons 41, 69, 70, 74, 184 and 215.
Rusconi S; La Seta Catamancio S; Sheridan F; Parker D
J Clin Virol; 2000 Dec; 19(3):135-42. PubMed ID: 11090748
[TBL] [Abstract][Full Text] [Related]
20. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.
Coffie PA; Ekouevi DK; Chaix ML; Tonwe-Gold B; Clarisse AB; Becquet R; Viho I; N'dri-Yoman T; Leroy V; Abrams EJ; Rouzioux C; Dabis F
Clin Infect Dis; 2008 Feb; 46(4):611-21. PubMed ID: 18197758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
